Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | CHIEF MEDICAL OFFICER | September 17, 2026 | September 18, 2026 |
| iBio, Inc.IBIO · Entity 6906 | Director | October 14, 2026 | October 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SAB Biotherapeutics, Inc.
Report date September 17, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,853 |
Reported balance
After 2026-09-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-17 · Tax withholding · Disposed 473 · Balance 41,853 F1: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F2: Includes 38,402 shares of Common Stock and 3,433 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. F3: Each RSU represents a contingent right to receive one share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").
F2: Includes 38,402 shares of Common Stock and 3,433 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.
F3: Each RSU represents a contingent right to receive one share of Common Stock.
iBio, Inc.
Report date October 14, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2036-10-13 | Direct | 38,000 |
Reported balance
After 2026-10-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-14 · Grant · Acquired 38,000 · Balance 38,000 F1: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2026 Filed Oct 15, 2026 22:33 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-26-116321 · tm2627695-5_4seq1.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2036-10-13 F1 · security: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date. F1 · shares: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date. F1 · derivative.exercise_date: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:15 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | Tax withholdingCommon Stock | 473 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-395552 · ownership.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,853 F1 · shares: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F1 · price: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F2 · balance_after: Includes 38,402 shares of Common Stock and 3,433 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. F3 · balance_after: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 21:20 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | Tax withholdingCommon Stock | 988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-285722 · ownership.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,308 F1 · shares: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F1 · price: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F2 · balance_after: Includes 37,158 shares of Common Stock and 5,150 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. F3 · balance_after: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 20:35 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | Tax withholdingCommon Stock | 988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-124231 · ownership.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,296 F1 · shares: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F1 · price: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F2 · balance_after: Includes 34,553 shares of Common Stock and 8,743 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. F3 · balance_after: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:40 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock option (right to buy) · Derivative | 2,400,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001193125-26-039524 · ownership.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,400,000 Underlying: Common Stock · 2,400,000 shares Expires 2036-02-03 F1 · shares: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 21:45 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | Tax withholdingCommon Stock | 988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-317688 · ownership.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,284 F1 · shares: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F1 · price: Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs"). F2 · balance_after: Includes 31,946 shares of Common Stock and 12,338 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. F3 · balance_after: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:07 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-25-115409 · tm2532045-3_4seq1.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-11-19 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 21:00 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | Tax withholdingCommon Stock | 1,977 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-211490 · ownership.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,272 F1 · shares: Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). F1 · price: Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). F2 · balance_after: Includes 29,340 shares of Common Stock and 15,932 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. F3 · balance_after: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:00 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock Option (right to buy) · Derivative | 2,400,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0000950170-25-112047 · ownership.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,400,000 Underlying: Common Stock · 2,400,000 shares Expires 2035-08-26 F1 · shares: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan"). F2 · shares: The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder. F3 · derivative.exercise_date: The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| March 27, 2025 Filed Apr 1, 2025 20:19 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | Tax withholdingCommon Stock | 1,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048551 · ownership.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,249 F1 · security: Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). F1 · shares: Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). F1 · price: Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). F2 · balance_after: Includes 24,128 shares of Common Stock and 23,121 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. F3 · balance_after: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| December 18, 2024 Filed Dec 31, 2024 22:49 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | Tax withholdingCommon Stock | 9,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-141672 · ownership.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,428 F1 · security: Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). F1 · shares: Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). F1 · price: Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). F2 · balance_after: Includes 21,712 shares of Common Stock and 26,716 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. F3 · balance_after: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:32 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-122592 · tm2429436-4_4seq1.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires 2034-11-20 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:00 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0000950170-24-019460 · ownership.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2034-02-21 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:30 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantCommon Stock | 275,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-006913 · rdgdoc.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 F1 · security: Restricted Stock Unit ("RSU") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on March 14, 2024, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date. F1 · shares: Restricted Stock Unit ("RSU") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on March 14, 2024, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 21:00 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 18,325 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-22-050093 · doc4.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,325 Underlying: Common Stock · 18,325 shares Expires 2032-09-13 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 00:00 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034919 · doc4.xml · nonDerivative · entry 1 Kropotova Alexandra · CIK 0001825323 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · security: Restricted Stock Unit ("RSU") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on June 6, 2023, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date. F1 · shares: Restricted Stock Unit ("RSU") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on June 6, 2023, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 00:08 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001104659-21-149234 · tm2135158-1_4seq1.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2031-12-08 F1 · security: These options vest pro rata on a monthly basis over 12 months. F1 · shares: These options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 10:09 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001104659-20-115457 · tm2033244d5_form4.xml · derivative · entry 1 Kropotova Alexandra · CIK 0001825323 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-10-13 F1 · shares: These options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.